Your browser is no longer supported. Please, upgrade your browser.
ABEO Abeona Therapeutics Inc. monthly Stock Chart
ABEO [NASD]
Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own1.70% Shs Outstand92.64M Perf Week-1.36%
Market Cap243.60M Forward P/E- EPS next Y-0.80 Insider Trans-0.45% Shs Float67.23M Perf Month2.83%
Income-105.90M PEG- EPS next Q-0.17 Inst Own56.70% Short Float4.44% Perf Quarter-11.01%
Sales- P/S- EPS this Y-27.10% Inst Trans0.98% Short Ratio3.36 Perf Half Y-8.20%
Book/sh1.43 P/B2.03 EPS next Y22.30% ROA-60.50% Target Price- Perf Year21.76%
Cash/sh1.39 P/C2.10 EPS next 5Y- ROE-82.40% 52W Range1.35 - 5.19 Perf YTD-11.01%
Dividend- P/FCF- EPS past 5Y37.00% ROI- 52W High-44.80% Beta1.32
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low112.22% ATR0.18
Employees88 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)45.50 Volatility5.78% 5.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-34.30% Profit Margin- Rel Volume0.48 Prev Close2.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume886.41K Price2.87
Recom2.00 SMA20-2.30% SMA50-3.34% SMA2001.28% Volume244,231 Change-1.55%
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
Dec-16-15Initiated Maxim Group Buy $6
Jul-20-15Initiated MLV & Co Buy $15
Aug-10-20 04:01PM  
Aug-04-20 11:36AM  
Jul-10-20 07:30AM  
Jul-09-20 09:10AM  
07:30AM  
Jul-08-20 07:30AM  
Jul-03-20 07:48AM  
Jun-23-20 11:59AM  
Jun-18-20 07:30AM  
Jun-17-20 07:30AM  
Jun-08-20 09:11AM  
May-28-20 11:30AM  
08:30AM  
May-08-20 12:58PM  
May-07-20 01:59PM  
May-06-20 04:14PM  
Apr-29-20 11:08AM  
Apr-21-20 04:04PM  
08:00AM  
Apr-20-20 08:43AM  
06:06AM  
Apr-17-20 07:00AM  
Apr-06-20 09:16AM  
Apr-05-20 04:12AM  
Mar-27-20 06:19PM  
Mar-23-20 12:00PM  
Mar-17-20 07:30AM  
Mar-16-20 04:20PM  
Feb-26-20 08:00AM  
Feb-21-20 08:45AM  
Feb-12-20 02:15PM  
Jan-21-20 08:00AM  
Jan-15-20 09:33AM  
Jan-13-20 09:00AM  
Jan-02-20 12:12PM  
11:55AM  
10:28AM  
04:52AM  
Dec-31-19 12:30PM  
12:00PM  
Dec-27-19 08:30PM  
06:00PM  
Dec-24-19 02:20PM  
01:30PM  
01:01PM  
Dec-20-19 06:20PM  
10:44AM  
10:22AM  
10:00AM  
09:24AM  
Dec-19-19 05:20PM  
05:00PM  
01:03PM  
Dec-18-19 03:59PM  
Dec-17-19 02:25PM  
Dec-16-19 07:10PM  
10:51AM  
10:22AM  
Dec-15-19 10:00AM  
Dec-14-19 09:36AM  
Dec-13-19 04:30PM  
12:03PM  
10:00AM  
Dec-12-19 01:30PM  
10:00AM  
09:00AM  
Dec-11-19 05:17PM  
02:25PM  
09:48AM  
Dec-09-19 05:45PM  
01:06PM  
10:20AM  
08:45AM  
Dec-06-19 08:00PM  
04:25PM  
10:00AM  
08:55AM  
Dec-05-19 02:56PM  
09:58AM  
Dec-04-19 05:05PM  
05:00PM  
09:33AM  
Dec-03-19 09:29PM  
Dec-02-19 08:50PM  
05:50PM  
10:06AM  
06:33AM  
Nov-29-19 10:00AM  
Nov-27-19 03:05PM  
03:00PM  
02:20PM  
01:30PM  
Nov-25-19 07:00PM  
03:45PM  
10:40AM  
Nov-23-19 02:27PM  
02:24PM  
Nov-22-19 06:25PM  
03:00PM  
10:06AM  
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARR EDWARDChief Accounting OfficerMar 19Sale1.816,44611,66713,554Mar 20 04:14 PM
Buono StefanoDirectorDec 24Buy2.50200,000500,000270,000Dec 31 05:17 PM